Trametinib is a cancer medicine used for some melanomas, lung cancers, thyroid cancers and brain tumors that have a change in a gene called BRAF. It is taken by mouth as a pill, or as a liquid for children, usually together with another medicine called dabrafenib. It works by blocking a signal that tells cancer cells to grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Mekinist (Trametinib) for Melanoma?
Trametinib, sold as Mekinist, is a targeted cancer medicine taken by mouth. It is used only for cancers whose tumor tissue has been tested and found to carry a specific change in a gene called BRAF, known as a BRAF V600 mutation. Without that test result, it is not expected to help. In almost every approved use, trametinib is taken together with dabrafenib (Tafinlar), a second targeted medicine. The pair is approved for melanoma that has spread or cannot be removed with surgery, and for one year after surgery when melanoma has reached the lymph nodes, to lower the chance of it coming back. It is also approved for advanced non-small cell lung cancer, for anaplastic thyroid cancer (a fast-growing thyroid cancer) when surgery or radiation is not a good option, and for other advanced solid tumors in adults and children 1 year and older that have grown despite earlier treatment. That last use has accelerated approval, meaning it was granted on how often tumors shrank, and continued approval depends on further studies. In children 1 year and older, the combination also treats low-grade glioma, a slow-growing brain tumor, when medicine is needed. Trametinib can be used alone only for advanced melanoma in someone who has not already had a BRAF-blocking medicine. It is not used for colorectal cancer, even with a BRAF mutation, because those tumors find a way around the treatment.
Inside cells, a chain of proteins passes along signals that tell the cell when to grow and divide. BRAF is one link in that chain, and MEK is the next link after it. A BRAF V600 mutation leaves the BRAF link stuck in the on position, so the growth signal keeps flowing and the cancer keeps growing. Trametinib blocks MEK, cutting the signal further down the chain. Dabrafenib blocks the faulty BRAF itself. Hitting two links at once slows tumor growth more than either medicine alone, and in melanoma trials the combination kept the cancer controlled longer and helped people live longer than dabrafenib by itself. The same blockade also affects healthy tissues that use this signaling chain, such as skin, eyes and heart, which explains many of the side effects.
For adults, Mekinist tablets are usually taken once a day, at about the same time each day. Tablets are taken on an empty stomach, at least 1 hour before or 2 hours after a meal, and are swallowed without being crushed or broken. They come in a bottle with a moisture-absorbing packet and should stay in that bottle rather than a pill organizer. When trametinib is used with dabrafenib, each medicine has its own schedule: dabrafenib is taken twice a day. Children's doses are based on body weight. Older children who weigh enough can take tablets, while younger children use a liquid form that the pharmacist mixes and a caregiver gives with an oral syringe or feeding tube. Caregivers are shown how to measure and give it before starting. If a dose is missed, it can still be taken unless the next dose is due within 12 hours. If vomiting happens after a dose, do not take another one; take the next dose at the usual time. Side effects are often managed by pausing treatment or lowering the dose, so dose changes should come from the cancer care team rather than being made on your own.
When trametinib is taken with dabrafenib, fever is the most common side effect, affecting more than half of adults and children. It can come with chills, and sometimes with low blood pressure, dizziness, dehydration or kidney strain. Contact the care team when a fever starts; treatment is usually paused at a temperature of 100.4°F or higher and restarted once it settles. Other common effects include tiredness, nausea, vomiting, diarrhea, rash, headache, joint and muscle aches, swelling of the hands or legs, and higher blood pressure. Taken alone, trametinib most often causes rash, diarrhea and swelling. Some effects are less common but serious enough to report right away: any change in vision, a new or worsening cough or breathlessness, swollen ankles or a racing heartbeat that could signal a weakened heart, severe diarrhea or belly pain, unusual bleeding, or a rash that blisters or peels. With the combination, new skin cancers can appear, so new skin growths or changes in a mole are also worth reporting promptly. Sudden shortness of breath, chest pain, or a painful swollen arm or leg can mean a blood clot and needs emergency care. Heavy bleeding, vomiting blood, black stools, or a sudden severe headache or confusion that could signal bleeding in the brain also needs immediate medical attention.
Trametinib can harm a developing baby. A pregnancy test is done before starting, and effective contraception is needed during treatment and for 4 months after the last dose. Dabrafenib can make hormonal birth control, such as the pill, less effective, so people taking the combination are advised to use a non-hormonal method. Men whose partners could become pregnant should use condoms during treatment and for 4 months after, even after a vasectomy. Breastfeeding is not recommended during treatment or for 4 months after the last dose. Trametinib may also reduce female fertility, which is worth raising before treatment if future pregnancy matters. People with diabetes may find their blood sugar runs higher on the combination and may need their diabetes medicines adjusted. Dabrafenib also interacts with a number of other medicines, including the blood thinner warfarin, so the care team and pharmacist should have a complete list of prescriptions, over-the-counter medicines and supplements.
Treatment for advanced cancer usually continues as long as it keeps the cancer controlled and side effects are manageable. After surgery for melanoma, it is given for up to one year. Imaging scans at intervals show whether the cancer is responding. How well it works varies: many people see their tumors shrink or stay stable for a time, but in advanced cancer the disease often becomes resistant eventually, and the care team then discusses next options. Regular checks are part of the routine. A heart scan (an echocardiogram or similar test) measures how well the heart pumps before starting, after one month, and every 2 to 3 months after that. Blood pressure, blood tests and, for people with diabetes, blood sugar are monitored. Eye exams are done periodically and whenever vision changes. With dabrafenib, skin checks happen before treatment, about every 2 months during it, and for up to 6 months after stopping, to catch new skin cancers early. Pauses and dose changes are a normal part of this treatment. In melanoma studies of the combination, close to half of people had trametinib paused at some point, most often because of fever, and fewer than 1 in 5 needed a lower dose.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Mekinist (Trametinib), what you've noticed, or ask the community a question.